Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Xiaojie Bian, Dingwei Ye, Lijun Chen, Changlu Hu, Shusuan Jiang, Nianzeng Xing, Qingyun Zhang, Shuang Zhang, Jimin Chen, Fan Cheng, Guiling Li, Bin Hu, Gongxian Wang, Haitao Niu, Hui Chen, Jinjian Yang, Peng Zhang, Quan Yuan, Xi Gu, Yichao Chen
Institutions: Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Fudan University, Chinese People's Liberation Army, Hunan Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Sichuan University, West China Medical Center of Sichuan University, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Renmin Hospital of Wuhan University, Wuhan Union Hospital, Huazhong University of Science and Technology, Liaoning Cancer Hospital & Institute, First Affiliated Hospital of Nanchang University, Affiliated Hospital of Qingdao University, Third Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Zhengzhou University, Abbisko Therapeutics Co., Ltd. (China)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407698646